<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834806</url>
  </required_header>
  <id_info>
    <org_study_id>BioNIR-003</org_study_id>
    <nct_id>NCT02834806</nct_id>
  </id_info>
  <brief_title>BIONICS Israel Trial</brief_title>
  <official_title>BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medinol Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medinol Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the device success and the safety of Medinol's Drug Eluting Stent -&#xD;
      BioNIR - with a modified delivery system. The BioNIR Ridaforolimus Eluting Coronary Stent&#xD;
      System is a single use device/drug combination product comprising:&#xD;
&#xD;
        -  A mounted Cobalt Chromium (CoCr) alloy based stent&#xD;
&#xD;
        -  A Rapid Exchange (RX) delivery system&#xD;
&#xD;
        -  A polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®&#xD;
&#xD;
        -  Ridaforolimus drug - CAS Registry Number: 572924-54-0 It is indicated for improving&#xD;
           coronary luminal diameter in patients with symptomatic heart disease due to lesions in&#xD;
           vessels with reference diameters of 2.5 mm to 4.25 mm, including complex lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single arm, open label, clinical trial. Lesions planned&#xD;
      to be treated must be declared and recorded at time of enrollment. Planned staged procedures,&#xD;
      if necessary, must be declared immediately post procedure. Clinical follow-up will be&#xD;
      performed at 30 days.&#xD;
&#xD;
      Telephone follow-ups will be performed at 6 months and 1 year post procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">December 16, 2017</completion_date>
  <primary_completion_date type="Actual">January 16, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Success in the Target Lesion as Determined by the Angiographic Core Laboratory</measure>
    <time_frame>during baseline procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Success</measure>
    <time_frame>during baseline procedure</time_frame>
    <description>Lesion success is defined as achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA) using any percutaneous method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>during baseline procedure</time_frame>
    <description>Procedure success is defined as achievement of a final in-stent diameter stenosis of &lt;50% (by QCA) using the assigned device and/or with any adjunctive devices, without the occurrence of cardiac death, Q wave or non-Q wave MI, or repeat revascularization of the target lesion during the hospital stay.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Clinical follow-up will be performed at 30 days.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Telephone follow up will be performed at 6 months post procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Telephone follow up will be performed at 1 year post procedure</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Stenosis</condition>
  <arm_group>
    <arm_group_label>BioNIR drug eluting stent system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioNIR Ridaforolimus eluting coronary stent system with modified delivery system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioNIR Ridaforolimus Eluting Coronary Stent System</intervention_name>
    <description>BioNIR Ridaforolimus eluting coronary stent system with modified delivery system</description>
    <arm_group_label>BioNIR drug eluting stent system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with an indication for PCI including angina (stable or unstable), silent&#xD;
             ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis&#xD;
             of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be present), NSTEMI,&#xD;
             or recent STEMI. For STEMI the time of presentation to the first treating hospital,&#xD;
             whether a transfer facility or the study hospital, must be &gt;24 hours prior to&#xD;
             enrollment and enzyme levels (CK-MB or Troponin) demonstrating that either or both&#xD;
             enzyme levels have peaked.&#xD;
&#xD;
          2. Non-target vessel PCI are allowed prior to enrollment depending on the time interval&#xD;
             and conditions as follows:&#xD;
&#xD;
             During Baseline Procedure:&#xD;
&#xD;
             PCI of non-target vessels performed during the baseline procedure itself immediately&#xD;
             prior to enrollment if successful and uncomplicated defined as: &lt;50% visually&#xD;
             estimated residual diameter stenosis, TIMI Grade 3 flow, no dissection ≥ NHLBI type C,&#xD;
             no perforation, no persistent ST segment changes, no prolonged chest pain, no TIMI&#xD;
             major or BARC type 3 bleeding.&#xD;
&#xD;
             Less than 24 hours prior to Baseline Procedure:&#xD;
&#xD;
             Not allowed (see exclusion criteria #2). 24 hours-30 days prior to Baseline Procedure:&#xD;
             PCI of non-target vessels 24 hours to 30 days prior to enrollment if successful and&#xD;
             uncomplicated as defined above.&#xD;
&#xD;
             In addition, in cases where non-target lesion PCI has occurred 24-72 hours prior to&#xD;
             the baseline procedure, at least 2 sets of cardiac biomarkers must be drawn at least 6&#xD;
             and 12 hours after the non-target vessel PCI.&#xD;
&#xD;
             If cardiac biomarkers are initially elevated above the local laboratory upper limit of&#xD;
             normal, serial measurements must demonstrate that the biomarkers are falling.&#xD;
&#xD;
             Over 30 days prior to Baseline Procedure:&#xD;
&#xD;
             a. PCI of non-target vessels performed greater than 30 days prior to procedure whether&#xD;
             or not successful and uncomplicated.&#xD;
&#xD;
          3. Patient or legal guardian is willing and able to provide informed written consent and&#xD;
             comply with follow-up visits and testing schedule.&#xD;
&#xD;
             Angiographic inclusion criteria (visual estimate):&#xD;
&#xD;
          4. Target lesion(s) must be located in a native coronary artery or bypass graft conduit&#xD;
             with visually estimated diameter of ≥2.5 mm to ≤4.25 mm.&#xD;
&#xD;
          5. Complex lesions are allowed including calcified lesions (lesion preparation with&#xD;
             scoring/cutting and rotational atherectomy are allowed), presence of thrombus, CTO,&#xD;
             bifurcation lesions (except as noted in exclusion criteria #30), ostial RCA lesions,&#xD;
             tortuous lesions, bare metal stent restenotic lesions, protected left main lesions,&#xD;
             and saphenous vein graft lesions.&#xD;
&#xD;
          6. Overlapping stents are allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. STEMI within 24 hours of initial time of presentation to the first treating hospital,&#xD;
             whether at a transfer facility or the study hospital or in whom enzyme levels (either&#xD;
             CK-MB or Troponin) have not peaked.&#xD;
&#xD;
          2. PCI within the 24 hours preceding the baseline procedure.&#xD;
&#xD;
          3. Non-target lesion PCI in the target vessel within 12 months of the baseline procedure.&#xD;
&#xD;
          4. History of stent thrombosis.&#xD;
&#xD;
          5. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure &lt;90&#xD;
             mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support,&#xD;
             including IABP.&#xD;
&#xD;
          6. Subject is intubated.&#xD;
&#xD;
          7. Known LVEF &lt;30%.&#xD;
&#xD;
          8. Relative or absolute contraindication to DAPT for 6 months in non-ACS patients and 12&#xD;
             months in ACS patients (including planned surgeries that cannot be delayed, or subject&#xD;
             is indicated for chronic oral anticoagulant treatment).&#xD;
&#xD;
          9. Calculated creatinine clearance &lt;30 mL/min using Cockcroft-Gault equation (&lt;40 mL/min&#xD;
             for subjects participating in the angiographic follow-up sub-study).&#xD;
&#xD;
         10. Hemoglobin &lt;10 g/dL.&#xD;
&#xD;
         11. Platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3.&#xD;
&#xD;
         12. White blood cell (WBC) count &lt;3,000 cells/mm3.&#xD;
&#xD;
         13. Clinically significant liver disease.&#xD;
&#xD;
         14. Active peptic ulcer or active bleeding from any site.&#xD;
&#xD;
         15. Bleeding from any site within the prior 8 weeks requiring active medical or surgical&#xD;
             attention.&#xD;
&#xD;
         16. If femoral access is planned, significant peripheral arterial disease which precludes&#xD;
             safe insertion of a 6F sheath.&#xD;
&#xD;
         17. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.&#xD;
&#xD;
         18. Cerebrovascular accident or transient ischemic attack within the past 6 months, or any&#xD;
             permanent neurologic defect attributed to CVA.&#xD;
&#xD;
         19. Known allergy to the study stent components, cobalt, nickel, chromium, molybdenum,&#xD;
             Carbosil®, PBMA, polymer, or limus drugs (ridaforolimus, zotarolimus, tacrolimus,&#xD;
             sirolimus, everolimus, or similar drugs or any other analogue or derivative or similar&#xD;
             compounds).&#xD;
&#xD;
         20. Known allergy to protocol-required concomitant medications such as aspirin, or DAPT&#xD;
             (clopidogrel, prasugrel, ticagrelor), or heparin and bivalirudin, or iodinated&#xD;
             contrast that cannot be adequately pre-medicated.&#xD;
&#xD;
         21. Any co-morbid condition that may cause non-compliance with the protocol (e.g.&#xD;
             dementia, substance abuse, etc.) or reduced life expectancy to &lt;24 months (e.g.&#xD;
             cancer, severe heart failure, severe lung disease).&#xD;
&#xD;
         22. Patient is participating in or plans to participate in any other investigational drug&#xD;
             or device clinical trial that has not reached its primary endpoint.&#xD;
&#xD;
         23. Women who are pregnant or breastfeeding (women of child-bearing potential must have a&#xD;
             negative pregnancy test within one week before treatment).&#xD;
&#xD;
         24. Women who intend to become pregnant within 12 months after the baseline procedure&#xD;
             (women of child-bearing potential who are sexually active must agree to use a reliable&#xD;
             method of contraception from the time of screening through 12 months after the&#xD;
             baseline procedure).&#xD;
&#xD;
         25. Patient has received an organ transplant or is on a waiting list for an organ&#xD;
             transplant.&#xD;
&#xD;
         26. Patient is receiving or scheduled to receive chemotherapy within 30 days before or any&#xD;
             time after the baseline procedure.&#xD;
&#xD;
         27. Patient is receiving oral or intravenous immunosuppressive therapy or has known&#xD;
             life-limiting immunosuppressive or autoimmune disease (e.g., HIV). Corticosteroids are&#xD;
             allowed.&#xD;
&#xD;
             Angiographic Exclusion Criteria (visual estimate):&#xD;
&#xD;
         28. More than 100 mm length of planned stenting in the entire coronary tree.&#xD;
&#xD;
         29. Unprotected left main lesions ≥30%, or planned left main intervention.&#xD;
&#xD;
         30. Ostial LAD or LCX lesions (stenting of any diseased segment within 5 mm of the&#xD;
             unprotected left main coronary artery).&#xD;
&#xD;
         31. Bifurcation lesions with planned dual stent implantation.&#xD;
&#xD;
         32. Stenting of lesions due to DES restenosis.&#xD;
&#xD;
         33. Another lesion in a target or non-target vessel (including all side branches) is&#xD;
             present that requires or has a high probability of requiring PCI within 12 months&#xD;
             after the baseline procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abid Assali, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shmuel Banai, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Souraski Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Jonas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaplan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>July 3, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>September 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2020</results_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BioNIR Drug Eluting Stent System</title>
          <description>BioNIR Ridaforolimus eluting coronary stent system with modified delivery system&#xD;
BioNIR Ridaforolimus Eluting Coronary Stent System: BioNIR Ridaforolimus eluting coronary stent system with modified delivery system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BioNIR Drug Eluting Stent System</title>
          <description>BioNIR Ridaforolimus eluting coronary stent system with modified delivery system&#xD;
BioNIR Ridaforolimus Eluting Coronary Stent System: BioNIR Ridaforolimus eluting coronary stent system with modified delivery system</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Device Success in the Target Lesion as Determined by the Angiographic Core Laboratory</title>
        <time_frame>during baseline procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BioNIR Drug Eluting Stent System</title>
            <description>BioNIR Ridaforolimus eluting coronary stent system with modified delivery system&#xD;
BioNIR Ridaforolimus Eluting Coronary Stent System: BioNIR Ridaforolimus eluting coronary stent system with modified delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success in the Target Lesion as Determined by the Angiographic Core Laboratory</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Success</title>
        <description>Lesion success is defined as achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA) using any percutaneous method.</description>
        <time_frame>during baseline procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Success</title>
        <description>Procedure success is defined as achievement of a final in-stent diameter stenosis of &lt;50% (by QCA) using the assigned device and/or with any adjunctive devices, without the occurrence of cardiac death, Q wave or non-Q wave MI, or repeat revascularization of the target lesion during the hospital stay.</description>
        <time_frame>during baseline procedure</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Major Adverse Cardiac Events (MACE)</title>
        <time_frame>Clinical follow-up will be performed at 30 days.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Major Adverse Cardiac Events (MACE)</title>
        <time_frame>Telephone follow up will be performed at 6 months post procedure</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Major Adverse Cardiac Events (MACE)</title>
        <time_frame>Telephone follow up will be performed at 1 year post procedure</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Investigator monitored the occurrence of adverse events or device deficiencies for each subject during the whole course of the trial, baseline and post procedure, 30 days, 6 months and 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BioNIR Drug Eluting Stent System</title>
          <description>BioNIR Ridaforolimus eluting coronary stent system with modified delivery system&#xD;
BioNIR Ridaforolimus Eluting Coronary Stent System: BioNIR Ridaforolimus eluting coronary stent system with modified delivery system</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Peri procedureal MI</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Non specific chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dina Kofler, VP Clinical Affairs</name_or_title>
      <organization>Medinol</organization>
      <phone>+97237679032</phone>
      <email>dinak@medinol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

